Matthew Fowler-Watters

This inventor holds 8 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Arrowhead Pharmaceuticals, Inc., Sixth Streetlending Partners, as the Administrative Agent. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Fowler-Watters. Retrieved from https://idiyas.com/inventor/matthew-fowler-watters

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 6.6

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

7 out of 102

Arrowhead Pharmaceuticals, Inc.

patents

1 out of 4

Sixth Streetlending Partners, as the Administrative Agent

patents

Years Active: 2021-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12667619 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-06-30),

2. 12582718 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-03-24),

3. 12527877 - ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF (2026-01-20),

4. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

5. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),

6. 12065458 - Trialkyne linking agents and methods of use (2024-08-20),

7. 11597701 - Integrin ligands and uses thereof (2023-03-07),

8. 11180529 - Alpha-v beta-6 integrin ligands and uses thereof (2021-11-23),

Title: Innovations of Matthew Fowler-Watters

Introduction

Matthew Fowler-Watters is a notable inventor based in Madison, WI (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. With a total of five patents to his name, Fowler-Watters is recognized for his innovative approaches to treating various diseases.

Latest Patents

Fowler-Watters' latest patents include groundbreaking work on RNAi agents for inhibiting the expression of HIF-2 alpha. This patent describes double-stranded RNAi agents capable of inhibiting the HIF-2 alpha (EPAS1) gene expression. The disclosure also includes pharmaceutical compositions that incorporate these RNAi agents and methods for their use. These agents can be linked to targeting ligands, enhancing their delivery to cells and tissues, particularly in treating clear cell renal cell carcinoma (ccRCC). Another significant patent involves integrin ligands that exhibit serum stability and affinity for αvβ6 integrins, along with methods for their application.

Career Highlights

Matthew Fowler-Watters is currently employed at Arrowhead Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work focuses on innovative therapeutic solutions that leverage RNAi technology to address critical health challenges.

Collaborations

Fowler-Watters collaborates with esteemed colleagues, including Zhen Li and Jeffrey Carlson, to further enhance the impact of their research in the biotechnology sector.

Conclusion

Matthew Fowler-Watters exemplifies the spirit of innovation in biotechnology through his patents and research contributions. His work on RNAi agents and integrin ligands holds promise for advancing treatment options for various diseases.

Profile summary based on public USPTO records.